Plus Therapeutics, Inc. (PSTV) has announced the appointment of Kyle Guse to its Board of Directors. Guse will take on the role of chair of the Audit Committee and will also serve on the Compensation Committee. His addition is expected to bring significant legal and financial expertise to the company.
Guse currently holds the position of Chief Legal Officer at DDC Enterprise (DDC, Financial), where he has gained extensive experience in corporate legal matters. His background is anticipated to enhance Plus Therapeutics' strategic governance and oversight practices.
The appointment of Guse is seen as part of Plus Therapeutics' ongoing efforts to strengthen its leadership team and support its business objectives moving forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for DDC Enterprise Ltd (DDC, Financial) is $25.00 with a high estimate of $25.00 and a low estimate of $25.00. The average target implies an upside of 1,113.59% from the current price of $2.06. More detailed estimate data can be found on the DDC Enterprise Ltd (DDC) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, DDC Enterprise Ltd's (DDC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
